In our rearview mirror is a ten-year stretch of experimentation. What looms ahead is the rewriting of healthcare's rules.
A closer look at how fast change may happen, who could win (and lose), and how the next decade may unfold for incumbents and new market entrants.
Our most popular articles of the year offered our predictions on disruption and the future market, and highlighted our views on healthcare reform, ACOs, and much more.
Purposeful collaboration will help more people understand how their daily decisions dictate their health.
Advice on how the healthcare industry can address the pharmaceutical cost problem.
In light of breaking news, the pharma value chain is definitely ripe for disruption. Here's how health plans, employers, and drug companies can adjust to the new normal.
2018 has already seen transformational industry news. Here we dig deeper and analyze what the industry can expect in M&A, investments, pharma and much more.
Partners Sam Glick and Sven-Olaf Vathje write in Harvard Business Review on how countries around the world can learn from a broken American healthcare system.
What's around the bend for healthcare venture capital in 2018? We talk Amazon, good and bad M&A, and hitting the investment peak.
As one of the fastest-rising categories of healthcare costs, pharmaceuticals need to develop a metric that explains pricing.